US 10,376,565 B2
Method of diagnosis and treatment
Belinda Sheree Parker, Victoria (AU); and Paul John Hertzog, Victoria (AU)
Assigned to LA TROBE UNIVERSITY, Victoria (AU)
Appl. No. 14/415,832
Filed by LA TROBE UNIVERSITY, Bundoora, Victoria (AU)
PCT Filed Jul. 19, 2013, PCT No. PCT/AU2013/000801
§ 371(c)(1), (2) Date Jan. 20, 2015,
PCT Pub. No. WO2014/012147, PCT Pub. Date Jan. 23, 2014.
Claims priority of application No. 2012903104 (AU), filed on Jul. 20, 2012.
Prior Publication US 2015/0174205 A1, Jun. 25, 2015
Int. Cl. C12Q 1/6886 (2018.01); A61K 38/21 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); A61K 31/4745 (2006.01)
CPC A61K 38/21 (2013.01) [A61K 31/4745 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57484 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/56 (2013.01); G01N 2333/7156 (2013.01)] 9 Claims
 
1. A method of diagnosing and treating metastatic breast tumour in an individual, said method comprising:
(i) obtaining a biological sample of a primary breast tumour from said individual;
(ii) detecting the expression level of interferon regulatory factor 7 (IRF7) and interferon regulatory factor 9 (IRF9) in said tumour;
(iii) diagnosing a metastatic phenotype of said tumour when the expression level of said IRF7 and IRF9 is decreased in comparison to a non-metastatic breast tumour;
(iv) administering an effective amount of an agent to the diagnosed individual, wherein the agent is a Toll-like receptor (TLR) agonist selected from the group consisting of interferon alpha (IFN α), poly I:C and imiquimod, and wherein the agent increases the level of Type I interferon (IFN) in the diagnosed individual.